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Abstract
Background: A novel series of methylene-substituted DIMs (C-DIMs), namely 1,1-bis(3’-indolyl)-1-(p-substituted
phenyl)methanes containing t-butyl (DIM-C-pPhtBu) and phenyl (DIM-C-pPhC6H5) groups inhibit proliferation of
invasive estrogen receptor-negative MDA-MB-231 and MDA-MB-453 human breast cancer cell lines with IC50
values between 1-5 uM. The main purpose of this study was to investigate the pathways of C-DIM-induced cell
death.
Methods: The effects of the C-DIMs on apoptotic, necrotic and autophagic cell death were determined using
caspase inhibitors, measurement of lactate dehydrogenase release, and several markers of autophagy including
Beclin and light chain associated protein 3 expression (LC3).
Results: The C-DIM compounds did not induce apoptosis and only DIM-C-pPhCF3 exhibited necrotic effects.
However, treatment of MDA-MB-231 and MDA-MB-453 cells with C-DIMs resulted in accumulation of LC3-II
compared to LC3-I protein, a characteristic marker of autophagy, and transient transfection of green fluorescent
protein-LC3 also revealed that treatment with C-DIMs induced a redistribution of LC3 to autophagosomes after
C-DIM treatment. In addition, the autofluorescent drug monodansylcadaverine (MDC), a specific
autophagolysosome marker, accumulated in vacuoles after C-DIM treatment, and western blot analysis of lysates
from cells treated with C-DIMs showed that the Beclin 1/Bcl-2 protein ratio increased.
Conclusion: The results suggest that C-DIM compounds may represent a new mechanism-based agent for treating
drug-resistant ER-negative breast tumors through induction of autophagy.
Background
Studies in this laboratory have investigated the mechan-
isms of cell death induced by a new series of anticancer
agents that are derivatives of phytochemicals expressed
in crucifers. Indole-3-carbinol is a phytochemical found
as a conjugate in cruciferous vegetables, and both
indole-3-carbinol and one of its major metabolites, 3,3’-
diindolylmethane (DIM), exhibit a broad range of antic-
ancer and antitumorigenic activities against multiple
tumor types [1-6]. Epidemiology studies have correlated
consumption of cruciferous vegetables with decreased
risk for certain types of cancer [7-11], and indole-3-car-
binol and DIM may contribute to cancer chemopreven-
tion associated with these vegetables. The mechanisms
of growth inhibition induced by DIM have been well-
studied and include G0/G1 cell cycle arrest, induction of
ER stress, induction of apoptosis, activation of aryl
hydrocarbon receptor (AhR)-dependent antiestrogeni-
city, and downregulation of the androgen receptor (AR)
[2,5,12-18]. We also synthesized several DIMs substi-
tuted in the indole ring and at the methylene carbon
bridge to determine structure-activity relationships.
A novel series of methylene-substituted DIMs (C-
DIMs), namely 1,1-bis(3’-indolyl)-1-(p-substituted phe-
nyl)methanes containing t-butyl (DIM-C-pPhtBu) and
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phenyl (DIM-C-pPhC6H5) groups, activate peroxisome
proliferator-activated receptor g (PPARg) and induce
receptor-dependent and -independent growth inhibitory
and pro-apoptotic responses/genes in colon, pancreatic,
ovarian, prostate, bladder and breast cancer cells and/or
tumors [19-25]. In ER-negative breast cancer cells, the
effect of PPARg-active C-DIMs on the cell cycle, induc-
tion of the pro-apoptotic protein NAG-1, and activation
of kinases is primarily receptor-independent and effects
of C-DIMs on % distribution of MDA-MB-231 and
MDA-MB-453 cells in G0/G1, S and G2/M were mini-
mal [26]. Although C-DIMs modulate Bax and Bcl-2
protein expression, PARP is not cleaved, suggesting a
caspase-independent form of cell death [26]. Therefore,
the mechanism of cell death induced by C-DIMs in
breast cancer cells requires further examination.
In the present study, treatment of ER-negative MDA-
MB-231 and MDA-MB-453 cells with C-DIMs did not
activate caspases or increase Annexin V staining, indi-
cating that apoptotic cell death was not activated [26].
These observations prompted us to examine other cell
death pathways including necrosis and autophagy. The
latter pathway is important for cellular homeostasis but
can also be activated by some anticancer agents. Mea-
surement of LDH release and propidium iodide (PI)
staining suggested that necrosis was not the major form
of cell death induced in ER-negative breast cancer cells
treated with C-DIMs. In contrast, autophagolysosomes
were positively stained with monodansylcadaverine
(MDC) after treatment with C-DIMs, and there was a
significant increase in LC3b and Beclin 1/Bcl-2 protein
ratios. In addition, after treatment with C-DIMs, trans-
fected GFP-LC3 localized to autophagosomal mem-
branes of cells. These data support a contributing role
of autophagy in the mechanism of action of C-DIMs in
ER-negative breast cancer cells.
Methods
Cells, chemicals and other materials
NADH, zVAD-fmk and PI were obtained from Sigma
Chemical Co. (St. Louis, MO). MDC was purchased
from Fluka (Buchs, Switzerland). The human breast can-
cer cell lines MDA-MB-231 and MDA-MB-453 were
obtained from American Type Culture Collection (Man-
assas, VA). MDA-MB-231 cells were maintained in
DMEM:F-12 supplemented with 0.22% sodium bicarbo-
nate, 10% fetal bovine serum (FBS), and 2 ml/L antibio-
tic solution (Sigma Chemical Co., St. Louis, MO).
MDA-MB-453 cells were maintained in RPMI supple-
mented with 0.22% sodium bicarbonate, 10% FBS, and 2
ml/L antibiotic solution (Sigma Chemical Co., St. Louis,
MO). Cells were grown in 150 cm2 culture plates in an
air/CO2 (95:5) atmosphere at 37°C and passaged every 5
days. Beclin 1 (H-300) and Bcl-2 (N-19) antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). The LC3 antibody was purchased from MBL Inter-
national (Woburm, MA). Horseradish peroxidase sub-
strate for Western blot analysis was purchased from
NEN Life Science Products (Boston, MA).
Cell proliferation assay
MDA-MB-231 and MDA-MB-453 cells were seeded at a
density of 3-5 × 104/well in 12-well plates and media
was replaced the next day with DMEM:F-12 media con-
taining 2.5% charcoal-stripped FBS and pre-treated with
20 μM zVAD-fmk or vehicle control for 30 min. Cells
were then co-treated with zVAD-fmk or vehicle control
and DMSO or 10 μM DIM-C-pPhCF3, DIM-C-pPhtBu
or DIM-C-pPhC6H5 for 48 h. Cells were then counted
using a Coulter Z1 cell counter. Each experiment was
completed in triplicate and results are expressed as
means ± SE for each determination.
Annexin V staining
MDA-MB-231 and MDA-MB-453 cells were seeded at a
density of 2.5-5 × 105/well in 6-well plates and media
was replaced the next day with DMEM:F-12 media con-
taining 2.5% charcoal-stripped FBS and DMSO or 10
mM DIM-C-pPhCF3, DIM-C-pPhtBu or DIM-C-
pPhC6H5 for 48 h. Cells were also treated for 24 h with
10 mM MG132. Cells were then harvested according to
the Annexin-V-FITC protocol provided by BD Bios-
ciences. Briefly, floating cells were transferred to an
Eppendorf tube and centrifuged for 2 min at 3000 g.
The adherent cells were trypsinized and transferred to
the same Eppendorf which was spun and the superna-
tant was removed. Cells were resuspended in 85 ml of
1× Annexin V binding buffer and 10 ml of PI solution
(5 μg/mL). Five ml of Annexin V-FITC conjugate was
added to each sample and then incubated in the dark
for 15 min before analysis by flow cytometry which may
underestimate the number of dead cells due to fragmen-
tation of floating cells. Cells early in apoptosis positively
stained for Annexin V, whereas cells in the later stages
of apoptosis stained positively for Annexin V and PI due
to late apoptotic cells having leaky plasma membranes
(magnification = 400×).
PI and Hoechst staining
Vybrant Apoptosis Assay Kit #7 was used from Molecu-
lar Probes (Eugene, OR) according to the manufacturer’s
directions. Briefly, monolayers of cells were cultured for
48 h in 2-well Coverglass Chamber slides. Slides were
washed with culture medium without serum or phenol
red, and labeled with Hoechst 33343 and propidium
iodide at a final concentration of 5 μg/ml and 1.0 μg/ml,
respectively. The slides were incubated for 30 min
on ice and visualized using a BioRad Radiance 2000
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Multiphoton microscope. At least 3 areas per well were
analyzed. Two wells were analyzed per treatment and
per time point.
LDH assay
MDA-MB-231 and MDA-MB-453 cells were treated for
48 h with DMSO or C-DIMs as indicated. An extra 3
wells were treated for 1 h or until all cells had lysed
with 0.3% Triton X in PBS. For each sample, 200 μl of
1.22 mM pyruvate in 50 mM phosphate buffer and 4 μl
of 12.4 mg/ml NADH dissolved in 50 mM phosphate
buffer were each added to a 96-well plate. Twenty μl of
supernatant from treated cells was then added and the
plate was incubated at 37°C for 30 min. The LDH con-
centration was measured at 390 nm and the treated
groups were compared to Triton X, which was consid-
ered 100% LDH release.
MDC staining
Monolayers of cells were cultured for 48 h in 2-well
Coverglass Chamber slides and treated as indicated.
Slides were washed with culture medium without serum
or phenol red. Cytoplasmic vacuoles were stained with
MDC according to the method described [27]. Briefly,
cells were exposed to 50 mM of MDC for 10 min at 37°
C and visualized using a BioRad Radiance 2000 Multi-
photon microscope. At least 3 areas per well were ana-
lyzed. Two wells were analyzed per treatment and per
time point (magnification = 400×).
Western blots
MDA-MB-231 and MDA-MB-453 cells were seeded in
DMEM:F-12 media containing 2.5% charcoal-stripped
FBS for 24 h and then treated with either the vehicle
(DMSO) or the indicated compounds. In experiments
where indicated, cells were pre-treated for 30 min with
10 mM of the proteasome inhibitor MG132. Whole cell
lysates were obtained using high salt buffer [50 mM
HEPES, 500 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA,
10% glycerol and 1% Triton X-100 (pH 7.5) and 5 μl/ml
of Protease Inhibitor Cocktail]. Protein samples were
incubated at 100°C for 2 min, separated on 10-15%
SDS-PAGE at 120 V for 3-4 h in 1× running buffer [25
mM Tris-base, 192 mM glycine, and 0.1% SDS (pH 8.3)]
and transferred to a polyvinylidene difluoride (PVDF)
membrane at 0.9 A for 90 min at 4°C in 1× transfer buf-
fer (48 mM Tris-HCl, 39 mM glycine, and 0.025% SDS).
The PVDF membrane was blocked in 5% TBST-Blotto
[10 mM Tris-HCl, 150 mM NaCl (pH 8.0), and 0.025%
Triton X-100 and 5% non-fat dry milk] with gentle
shaking for 30 min and incubated in fresh 5% TBST-
Blotto with 1:200-1:1000 primary antibody overnight at
4°C with gentle shaking. After washing with TBST for
10 min, the PVDF membrane was incubated with
secondary antibody (1:5000) in 5%TBST-Blotto for 2 h.
The membrane was washed with TBST for 10 min and
incubated with 10 ml of chemiluminescence substrate
for 1.0 min and exposed to Kodak X-OMAT AR autora-
diography film. Band intensities were evaluated by scan-
ning laser densitometry (Sharp Electronic Corporation,
Mahwah, NJ) using Zero-D Scanalytics software (Scana-
lytics Corporation, Billerica, MA).
GFP-LC3 localization
Monolayers of cells were cultured for 48 h in 2-well
Coverglass Chamber slides and treated as indicated. The
GFP-LC3 plasmid was kindly provided by Dr. Tamotsu
Yoshimori (Osaka University, Osaka, Japan). MDA-MB-
231 cells were transfected with 500-600 ng/well of GFP-
LC3 plasmid using Lipofectamine transfection reagent
(Invitrogen, Carlsbad, CA) according to the manufac-
turer’s protocol. MDA-MB-453 cells were transfected
with 600 ng/well of GFP-LC3 plasmid using GeneJuice
transfection reagent (EMD Biosciences, Madison, WI)
according to the manufacturer’s protocol. Cells with
GFP-LC3 expression were counterstained with Hoechst
DNA dye from Molecular Probes (Eugene, OR). Slides
were examined by fluorescence microscopy using a
Zeiss Stallion Dual Detector Imaging System (Carl Zeiss
Microimaging Inc., Thornwood, NY). The intracellular
distribution of GFP-LC3 was evaluated by monitoring
GFP-LC3 and Hoechst fluorescence and DIC images
throughout the entire thickness of the cell by acquiring
optical slices at 0.5 μm intervals using a C-Apochromat
63×, 1.2 NA water immersion lens. Digital images were
acquired using Slide Book software (Intelligent Imaging
Innovations, Denver, CO). The entire z-stack was sub-
jected to fluorescence deconvolution to remove out-of-
plane fluorescence. Cells were examined in more than 5
fields per slide on multiple slides. Data represents the
average of all the fields.
Beclin-1 immunohistochemistry in tumors
The generation of tumors was performed as described
previously [26] in 4-6 week old female Balb/c athymic
nude mice (Nu-/-). All procedures were performed in
accordance with the National Institutes of Health
“Guide for the Care and Use of Laboratory Animals”
and were approved by the Institutional Animal Care and
Use Committee of Texas A&M University. Briefly, mice
were injected subcutaneously in the left flank with 107
MDA-MB-231 cells in 100 - 200 μl serum-free medium.
Groups of mice (12 mice/group) were then treated i.p.
with 40 mg/kg DIM-C-pPhC6H5 in 50 μl corn oil, or 50
μl corn oil, every day for 35 total injections starting at
day 4 post-tumor inoculations.
Tumor Beclin-1 expression was evaluated on 7-μm
thick formalin-fixed, paraffin-embedded tissue sections
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by a standard immunohistochemistry protocol. Briefly,
endogenous peroxidase was blocked by the use of 3%
hydrogen peroxide in PBS for 10 min. The slides were
then washed with distilled water for 2 min and this
washing step was repeated twice. Slides were then incu-
bated for 30 min at room temperature with a protein
blocking solution (VECTASTAIN Elite ABC kit, Vector
Laboratories, Burlingame, CA). Excess blocking solution
was drained, and the samples were incubated overnight
at 4°C at a 1:100 dilution of anti-rabbit Beclin 1 anti-
body. Sections were then incubated with biotinylated
secondary antibody followed by streptavidin (VECTAS-
TAIN Elite ABC kit, Vector Laboratories, Burlingame,
CA). The color was developed by exposing the peroxi-
dase to diaminobenzidine reagent (Vector Laboratories,
Burlingame, Ca), and Beclin 1 expression was identified
by the brown-colored cytoplasmic staining. Tumors
from two different animals per treatment group were
evaluated.
Statistical analysis
Statistical differences between different groups were
determined by ANOVA followed by Bonferroni post
hoc test for multiple comparisons at P < 0.05 using
SuperAnova software. The data are presented as mean ±
standard error for at least 3 separate determinations for
each treatment.
Results
PPARg-active C-DIMs inhibit growth and activate cas-
pase-dependent apoptosis in colon cancer cells [23].
C-DIMs also inhibit growth of MDA-MB-231 and
MDA-MB-453 breast cancer cells; however, this was not
accompanied by caspase-dependent PARP cleavage [26].
Figure 1A and 1B show that there was no statistically
significant reversal of C-DIM-mediated cell growth inhi-
bition after co-treatment of MDA-MB-231 and MDA-
MB-453 cells with the pan-caspase inhibitor zVAD-fmk,
suggesting that growth inhibition by the C-DIM com-
pounds was apoptosis-independent.
MDA-MB-231 and MDA-MB-453 cells were treated
with C-DIMs for 48 h, co-stained with Annexin V-FITC
conjugate which is a marker of apoptosis and PI and
analyzed by flow cytometry (Figure 1C and 1D). PI is a
DNA dye that is impermeable to cells with intact mem-
branes and is a marker of late apoptotic or necrotic cells
that have lost membrane integrity. Early apoptotic cells
stain positive for Annexin V, whereas cells in the later
stages of apoptosis stain positively for both Annexin V
and PI. The majority of cells treated with solvent control
DMSO clustered in the quadrant negative for both
Annexin V and PI. After treatment with the apoptosis-
inducing compound MG132, there was a slight increase
in MDA-MB-231 (but not MDA-MB-453) cells staining
positively for Annexin V alone and a statistically signifi-
cant increase in cells staining positive for Annexin V
and PI in both cell lines, suggesting that cells treated
with MG132 were in the late stages of apoptosis. In
MDA-MB-231 cells treated with C-DIMs, there was a
decrease in the number of cells staining positively for
Annexin V alone, and increased staining for Annexin V
and PI was observed only for DIM-C-pPhtBu. In both
MDA-MB-231 and MDA-MB-453 cells staining for PI
alone was observed only after treatment with DIM-C-
pPhCF3. In addition, all 3 C-DIM compounds signifi-
cantly increased Annexin V and PI staining in MDA-
MB-453 cells, indicating that these cells exhibited the
prototypical characteristics of late stage apoptosis and
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Figure 1 Influence of pan-caspase inhibitor zVAD-fmk on
growth inhibition induced by C-DIMs. MDA-MB-231 [A] and
MDA-MB-453 [B] cells were treated for 48 h with 10 μM DIM-C-
pPhCF3 (CF3), DIM-C-pPhtBu (tBu) or DIM-C-pPhC6H5 (C6H5) and
with or without 20 μM zVAD-fmk and then counted as described in
the Materials and Methods. Results of all proliferation studies are
presented as means ± SE for at least three separate determinations
for each treatment group. Significantly (p < 0.05) decreased growth
(compared to DMSO) in cells treated with C-DIMs alone is indicated
(*). FACS analysis of MDA-MB-231 [C] and MDA-MB-453 [D] cells co-
stained with Annexin V and PI. Cells were treated for 48 h or 24 h
with 10 μM MG132. Floating and adherent cells were incubated
with Annexin V and PI and analyzed by flow cytometry as described
in the Materials and Methods. Results of all proliferation studies are
presented as means ± SE for at least three separate determinations
for each treatment group. Significance (p < 0.05) compared to
DMSO is indicated (*).
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necrosis (Figure 1D). The failure of C-DIMs to induce
Annexin V alone indicates that the ER-negative breast
cancer cells do not undergo the early stages of apoptosis
and this was consistent with previous studies in these
cell lines treated with C-DIMs for only 24 h [26]. The
increased number of cells staining positive for both
Annexin V and PI are indicative of C-DIM-induced
loss of cell membrane integrity but Annexin V/PI stain-
ing does not identify which cell death pathways are
activated.
Some MDA-MB-231 cells were stained with PI after
treatment with C-DIMs; however, PI staining was not
observed in MDA-MB-453 cells treated with C-DIMs
(Figure 2A and 2B). LDH release from cells was signifi-
cantly elevated after treatment with the lytic agent, Tri-
ton X in both cell lines; however, among the three
PPARg-active C-DIMs only DIM-C-pPhCF3 significantly
increased levels of LDH release in MDA-MB-231 cells,
whereas none of the PPARg-active C-DIMs induced
LDH release in MDA-MB-453 cells (Figure 2C and 2D).
Thus, only DIM-C-pPhCF3 significantly induced necro-
sis in one of the two cell lines, suggesting that necrosis
was not the predominant death pathway induced by
PPARg-active C-DIMs in ER-negative breast cancer
cells.
Several drugs that are cytotoxic to cancer cell lines
induce autophagic cell death [28-38] and, therefore, the
effects of C-DIMs on MDC localization, a positive mar-
ker for autophagolysosomes, was investigated. The C-
DIMs clearly induced MDC localization in vacuoles in
MDA-MB-231 cells, whereas in cells treated with
DMSO, a smaller number and size of vacuoles was
observed indicating low basal levels of autophagy in
these cells (Figure 3A). Thus, treatment with C-DIMs
increased the number and/or size of vacuoles in this cell
line. MDC was also localized in large vacuoles in MDA-
MB-453 cells treated with DIM-C-pPhtBu and DIM-C-
pPhC6H5 (Figure 3B), whereas vacuole size and number
in cells treated with DIM-C-pPhCF3 resembled the con-
trol cells. These results suggest that DIM-C-pPhtBu and
DIM-C-pPhC6H5 induced autophagy in MDA-MB-231
and MDA-MB-453 cells.
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Figure 2 Necrosis detection by PI staining and LDH release.
MDA-MB-231 [A] and MCF-7 [B] cells were treated for 24 h with
DMSO or 10 μM DIM-C-pPhCF3, DIM-C-pPhtBu or DIM-C-pPhC6H5.
Two fluorescent DNA dyes Hoechst and propidium iodide, were
loaded into cells and incubated on ice for 30 min and visualized
using confocal microscopy as described in the Materials and
Methods. The same microscopic field of MDA-MB-231 [A] or MDA-
MB-453 [B] cells stained with Hoechst and propidium iodide are
shown and are representative of other cell areas with the same
treatment. At least 3 areas were scanned for each well and two
wells were analyzed per treatment and per time point. Width of
each field = 100 μm. LDH release after treatment with C-DIMs in
MDA-MB-231 [C] and MDA-MB-453 cells [D]. Cells were treated for
48 h or 1 h with 0.1% Triton X and the supernatants were analyzed
for LDH as described in the Materials and Methods. Triton X served
as a positive for 100% cell lysis and LDH release. Results are
presented as the means ± SE for at least three separate
determinations for each treatment group. Statistical significance of
treatments compared to DMSO (p < 0.05) are represented by an
asterisk.
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Figure 3 Detection of lysosomal activity with monodan-
sylcadaverine (MDC) staining. MDA-MB-231 [A] and MDA-MB-453
cells [B] were treated with DMSO or 10 μM DIM-C-pPhCF3, DIM-C-
pPhtBu or DIM-C-pPhC6H5 for 24 h. MDC was loaded into cells and
incubated at 37°C for 10 min and visualized using confocal
microscopy as described in the Materials and Methods. At least 5
areas were scanned for each well and images represented are
characteristic of treatment replicates. Width of each field is 100 μm
except for right two panels in [A] which are 50 μm.
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LC3b is critical for autophagosome formation and
after induction of autophagy, LC3b-I is lipidated to
LC3b-II which localizes to autophagosomal membranes,
and the ratio of LC3b-II to LC3b-I protein expression is
an indicator of autophagosome formation [39]. Confocal
microscopy images of a GFP-LC3 construct transiently
transfected into the two cell lines showed that in
untreated or DMSO-treated cells, there was a diffuse
GFP staining pattern (punctae), whereas after treatment
with C-DIMs, GFP-LC3 was primarily localized in
vacuoles (Figure 4A and 4B). In MDA-MB-231 cells,
there was an increase in the number of vacuoles posi-
tively stained for GFP-LC3 after treatment with DIM-C-
pPhtBu and DIM-C-pPhC6H5 compared to DMSO
(Figure 4A). The effect of DIM-C-pPhCF3 was less pro-
nounced than with the other two compounds in MDA-
MB-231 cells and this was consistent with the higher
necrotic activity of this compound (Figure 2). In MDA-
MB-453 cells, the size of the vacuoles was substantially
increased after treatment with DIM-C-pPhtBu, whereas
only the number of vacuoles increased in cells after
treatment with DIM-C-pPhC6H5 (Figure 4B). These data
suggest that C-DIM compounds activated autophagic
cell death pathways in MDA-MB-231 and MDA-MB-
453 cells.
Bafilomycin A1 inhibits maturation of autophago-
somes into autolysosomes by inhibiting fusion between
autophagosomes and lysosomes [40] and this compound
was used to further investigate the role of autophagy in
C-DIM-induced growth inhibition. Figure 5A shows that
DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-pPhC6H5
alone inhibit growth of MDA-MB-231 and MDA-MB-
453 cells. Their growth inhibitory effects were not
affected after treatment in combination with bafilomycin
and similar effects were observed with 3-methyladenine
(data not shown). These results indicate that induction
of autophagy by C-DIMs is not important for their inhi-
bition of cell growth. In untreated MDA-MB-231 cells,
both LC3b-I and LC3b-II proteins are expressed;
treatment with DIM-C-pPhCF3, DIM-C-pPhtBu and
DIM-C-pPhC6H5 increased expression of both proteins.
Bafilomycin alone increased accumulation of LC3b-II
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Figure 4 Translocation of GFP-LC3 after treatment with C-DIMs.
Translocation of transiently transfected GFP-LC3 plasmid. GFP-LC3
was transiently transfected into MDA-MB-231 [A] and MDA-MB-453
[B] and cells were treated with DMSO or 10 μM C-DIMs as outlined
in the Materials and Methods. Confocal microscopy images of live
cells were captured after treatment with C-DIMs for 24 h and
differential interference contrast (DIC) and DIC/GFP overlay images
of the same microscopic field are illustrated. At least 3 areas were
scanned per well and the images depicted are representative of
treatment replicates. Width of each field is 100 μm.
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Figure 5 Effects of bafilomycin on C-DIM-induced responses.
[A] Growth inhibition in breast cancer cells. MDA-MB-231 and MDA-
MB-453 cells were treated with DMSO, C-DIMs alone (10 μm), or in
combination with bafilomycin (150 nM) for 48 hr, and cells were
counted as described in the Materials and Methods. Results are
expressed as means ± SD for replicate (3) determinations. Effects of
bafilomycin on LC3b protein in MDA-MB-231 [B] and MDA-MB-453
[C] cells. Cells were treated with DMSO, C-DIMs alone, or in
combination with bafilomycin for 48 hr, and whole cell lysates were
analyzed by western blots as outlined in the Materials and Methods.
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protein and in combination with the C-DIM com-
pounds, LC3b-II levels were further increased compared
to bafilomycin alone, suggesting activation of autophagy
by the C-DIMs in this cell line. With the exception of
DIM-C-pPhtBu, similar results were observed in MDA-
MB-453 cells treated with bafilomycin alone or in com-
bination with C-DIMs. It is possible that DIM-C-pPhtBu
may affect clearance of the autophagic vesicles.
Although the same autophagy-related genes (Atg5,
Atg6, Atg7) play a role in autophagy and autophagic cell
death, both Atg5 and Atg6/Beclin 1 are upregulated in
autophagic cell death and remain low in autophagy [41].
The anti-apoptotic protein Bcl-2 has an inhibitory action
on Beclin 1 and the subsequent induction of autophagy
[42] and, therefore, the effects of C-DIMs on expression
of these proteins were further investigated. Treatment of
MDA-MB-231 cells with C-DIMs increased Beclin 1
and decreased Bcl-2 protein levels (Figure 6A), and in
MDA-MB-453 cells treated with C-DIMs, Beclin 1 pro-
tein levels increased only after treatment with DIM-C-
pPhtBu and DIM-C-pPhC6H5 and Bcl-2 protein was
decreased (Figure 6B). Densitometric analyses of these
proteins showed that C-DIMs increased Beclin 1/Bcl-2
ratios in MDA-MB-231 compared to that observed for
DMSO (Figure 6A); however, a statistically significant
increase in Beclin 1/Bcl-2 protein ratios was observed
only in MDA-MB-453 cells treated with DIM-C-pPhtBu
and DIM-C-pPhC6H5 (Figure 6B). In vivo studies
showed that DIM-C-pPhC6H5 inhibited growth of
tumors in nude mice bearing MDA-MB-231 cells as
xenografts [26]. We analyzed induction of autophagy in
these tumors after treatment with DIM-C-pPhC6H5 and
the results (Figure 6C) show enhanced staining of Beclin
1 in tumors from treated animals versus mice receiving
only corn oil (vehicle control). These results suggest
that C-DIMs induce cell death (Figure 1) in ER-negative
breast cancer cells and this may be partially due to acti-
vation of autophagy and this demonstrates the versatility
of this novel class of anticancer drugs which activate
multiple receptor-independent cell death pathways in
different cancer cell lines.
Discussion
C-DIMs inhibit ER-negative MDA-MB-231 and MDA-
MB-453 breast cancer cell proliferation and tumor
growth in athymic nude mice bearing MDA-MB-231
cells as xenografts. C-DIMs represent a novel series of
compounds that exert their growth inhibitory and anti-
tumorigenic effects in a cell context-dependent manner.
C-DIMs activate PPARg in a number of cancer cell
types including ovarian, bladder, colon, pancreatic and
ER-negative and ER-positive breast cancer cells
[19-22,24,25]. PPARg agonists inhibit cancer growth by
molecular mechanisms that include G1 cell cycle arrest,
induction of apoptosis and terminal differentiation
[43-46]. PPARg-active C-DIMs and other PPARg ago-
nists also activate PPARg-independent growth inhibitory
pathways including induction of NAG-1, ER stress and
apoptosis [20,47-52]. C-DIMs induce NAG-1 which is
proapoptotic in some cancer cell lines; however, in
MDA-MB-231 and MDA-MB-453 cells, these com-
pounds induced NAG-1 but not apoptosis. In addition,
induction of other receptor-dependent and -independent
pro-apoptotic and differentiation pathways such as ER
stress and caveolin 1 was not observed in ER-negative
breast cancer cells. Thus, the precise mechanism of C-
DIM-induced cell death in ER-negative breast cancer
cells is unclear and multiple pathways may be involved.
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Figure 6 Modulation of autophagy-related gene Beclin 1 and
Bcl-2 protein expression. MDA-MB-231 [A] and MDA-MB-453 [B]
cells were treated for 24 h with DMSO or C-DIMs, and whole cell
lysates were isolated and analyzed by Western blot analysis
according to procedures outlined in the Materials and Methods.
Densitometric analyses of Beclin 1 and Bcl-2 protein expression in
MDA-MB-231 and MDA-MB-453 cells was carried as described in the
Materials and Methods. Results are expressed as means ± SE for
three replicate determinations for each treatment group. *
Significantly different from DMSO (p < 0.05). [C] Enhanced tumor
staining of Beclin 1 after treatment with DIM-C-pPhC6H5 in nude
mice bearing MDA-MB-231 cells as xenografts. Fixed tumor tissue
from corn oil and DIM-C-pPhC6H5-treated mice [26] were stained
with Beclin 1 as described in the Materials and Methods. Results are
representative of tumors from two different animals per treatment
group. Width of each field is 230 μm.
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EB1089 is a vitamin D analog that induces caspase-
independent cell death in ER-positive MCF-7 and ER-
negative MDA-MB-231 and MDA-MB-453 breast can-
cer cells, and similar results were observed for C-DIMs
which also induced caspase-independent growth inhibi-
tion which could not be reversed after co-treatment
with the pan-caspase inhibitor zVAD-fmk (Figure 1).
We also confirmed that treatment with C-DIMs for 48
h did not induce Annexin V staining indicative of early
apoptotic cells in ER-negative breast cancer cells,
whereas the pro-apoptotic agent MG132 induced cells
staining with Annexin V staining in cells (Figure 1).
These results coupled with previous studies showing
that treatment with C-DIMs for 24 h did not induce
caspase-dependent PARP cleavage in these cell lines
[26] confirm that these compounds primarily induce
apoptosis-independent cell death. Other chemotherapeu-
tic agents such as the cytotoxic drug paclitaxel and
related analogs induced cell death in breast cancer cells;
however, only a small percentage of cells were under-
going apoptosis [29]. Thus, the current studies suggest
that an alternative form of cell death is induced by C-
DIMs in ER-negative breast cancer cells and this con-
trasts with the induction of caspase-dependent apoptosis
in ER-positive MCF-7 cells treated with C-DIMs [25].
Necrosis is an alternative form of cell death and
although initially considered an uncontrolled form of
cell demise, there is increasing evidence supporting the
concept of programmed necrosis [53]. For instance,
DNA damaging agents induced programmed cell death
in Bax-/-Bak-/- cells but only in actively proliferating
cells and these observations suggested an intrinsic cellu-
lar control point that decides cellular fate [54]. This
form of cell death is particularly appealing for che-
motherapeutic agents since many tumor cells have dys-
functional apoptotic pathways and, therefore, apoptosis-
inducing agents are not always effective for treating can-
cer [53]. In MDA-MB-231 cells, minimal staining of PI
and a statistically significant release of LDH was
observed only after treatment with DIM-C-pPhCF3;
signs of necrosis (PI staining) were also observed in
MDA-MB-231 cells treated with DIM-C-pPhtBu or
DIM-C-pPhC6H5 (Figure 2A and 2C). The lack of LDH
release and PI staining in MDA-MB-453 cells treated
with C-DIMs (Figure 2B and 2D) suggested that necro-
sis was not significantly induced in this cell line.
These results also indicate some structure-dependent
differences between C-DIMs and also with the structu-
rally-related ring-substituted DIMs. For example, 5,5’-
dibromoDIM induced necrotic cell death in ER-negative
MDA-MB-453 cells, whereas DIM-C-pPhtBu and DIM-
C-pPhC6H5 did not activate this cell death pathway [12].
Autophagic cell death is an alternative form of pro-
grammed cell death where cells lack the hallmarks of
apoptosis but there is an accumulation of autophagic
vacuoles in the cytoplasm [55], and several structurally
diverse chemotherapeutic agents induce autophagic cell
death in various cancer cell lines [28-30,32-34]. For
example, the PPARg agonist prostaglandin J2 induced
autophagic cell death in prostate cancer cells [34] and
the phytochemical sulforaphane induced autophagic cell
death in prostate cancer cells [28]. Therefore, we also
examined the effects of C-DIMs on activation of autop-
hagy in MDA-MB-231 and MDA-MB-453 breast cancer
cells. There are several biochemical methods for detect-
ing autophagic activity including acidic dyes that label
vacuoles which exhibit lysosomal activity [27]. Autopha-
gic cell death in prostate cancer cells treated with sulfor-
aphane exhibited lysosomotropic staining of cytoplasmic
vacuoles with acridine orange [28]. Other chemothera-
peutic candidate drugs induce signs of autophagy in
breast cancer cells [29,32,37,56]. Prenylated flavones
inhibited cell growth and induced autophagy in both
ER-positive MCF-7 and ER-negative MDA-MB-231
breast cancer cells and this response was typified by the
formation of cytoplasmic vacuoles that stained with the
autophagic marker MDC [56]. The vitamin D analog
EB1089 also inhibited cell growth in MCF-7 breast can-
cer cells and increased uptake of MDC into cytoplasmic
vacuoles [37]. These observations were similar to effects
of C-DIMs on ER-negative breast cancer cells which
also exhibited increased uptake of MDC into vacuoles
(Figure 3), suggesting that these compounds induce
autophagy. Therapeutic agents such as EB1089 and pre-
nylated flavones typically induce punctate lysosomotro-
pic staining, whereas treatment with DIM-C-pPhtBu in
particular induced formation of very large MDC-stained
vacuoles (Figure 3). These differences in staining may be
due, in part, to differences in the size of autophago-
somes in various cancer cell lines [57] caused by differ-
ences in autophagic flux.
LC3b, a critical protein involved in the early stage of
autophagosome formation, becomes lipidated upon
induction of autophagy [58]. Induction of LC3-II protein
expression, an increase in the ratio of LC3b-II/LC3b-I
expression, and translocation of LC3 to autophagosomal
membranes are diagnostic molecular markers indicative
of autophagy [39]. For example, treatment of breast can-
cer cells with camptothecin or paclitaxel analogs
increase the ratio of LC3b-II/LC3b-I protein expression
[29,59]. With the exception of DIM-C-p-PhCF3 in
MDA-MB-453 cells, treatment with C-DIMs induced
translocation of GFP-LC3 from the cytoplasm to autop-
hagosomal membranes (Figure 4A and 4B). Chemother-
apeutic agent EB1089 or radiation that induce
autophagic cell death typically induce GFP-LC3 staining
patterns in breast cancer cells similar to those observed
in this study with C-DIMs [33,37]. Bafilomycin blocks
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maturation of autophagosomes and in combination with
C-DIMs did not inhibit or enhance their growth inhibi-
tory effects in MDA-MB-231 and MDA-MB-453 cells
(Figure 5A). However, bafilomycin alone increased accu-
mulation of LC3b-II in both cell lines (Figure 5B and
5C) and with the exception of DIM-C-pPhtBu (MDA-
MB-453 cells), the C-DIM compounds further enhanced
bafilomycin-induced LC3b-II levels, suggesting activa-
tion of autophagy in these cells.
An important difference between autophagy as a sur-
vival mechanism versus autophagic cell death involves
the Atg5 and Atg6/Beclin 1 genes, which are upregu-
lated in autophagic cell death [41]. The anti-apoptotic
protein Bcl-2 is also critically involved as a negative reg-
ulator of the induction of autophagy by Beclin 1 [42].
Ceramide [60], camptothecin [61], and EB1089 [37]
induce autophagic cell death in breast cancer cells and
all of these agents increase Beclin 1 protein expression.
These observations are similar to the significant increase
of Beclin 1 protein levels and Beclin 1/Bcl-2 ratios in
MDA-MB-231 and MDA-MB-453 cells after treatment
with C-DIMs (Figure 6A and 6B) and also in tumors
from mice bearing MDA-MB-231 cells as xenografts
and treated with DIM-C-pPhC6H5 (Figure 6C). While
further studies that explore autophagic flux and the
actions of other autophagy inhibitors on C-DIM growth
inhibition are warranted, these findings represent the
first report to document the activation of an autophagic
program in ER-negative breast cancer cells with
C-DIMs.
Conclusions
In summary, results of this study demonstrate that
C-DIM compounds clearly decrease ER-negative breast
cancer cell proliferation and like some other cancer che-
motherapeutic drugs induce autophagy. These results
are in contrast to the mechanisms of action of C-DIMs
in colon, pancreatic, ovarian, prostate and bladder can-
cer cell lines where these same compounds induce both
PPARg-dependent and -independent growth inhibitory
and pro-apoptotic responses [19,20,22-25,47]. The
mechanisms associated with the cell context-dependent
differences in the anticancer activities of C-DIMs and
their mechanisms of growth inhibition and cell death in
ER-negative breast cancer cells are currently being
further investigated. The unusual activity of C-DIMs is
also being exploited for the clinical treatment of ER-
negative/highly invasive breast tumors that normally
only respond to highly cytotoxic drugs which induce
serious toxic side effects.
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